Effective **October 1, 2021**, the Alberta Biosimilars Initiative will be updated with the following changes that will affect adult members on Alberta government-sponsored drug plans.

**Addition of insulin aspart biosimilar – all adult patients on NovoRapid must switch by April 1, 2022**

1. **Update to Alberta Drug Benefit List (ADBL)**
   On October 1, 2021, a new insulin aspart biosimilar drug, Trurapi, was listed on the Alberta Drug Benefit List (ADBL) and will be subject to the Alberta Biosimilar Initiative.

2. **Coverage**
   Effective October 1, 2021, all new insulin aspart starts are covered with a biosimilar version of insulin aspart. Adult patients currently taking NovoRapid will be required to switch to a biosimilar version by April 1, 2022 to maintain coverage for this molecule through their Alberta government-sponsored drug plan.

Please note: patients that require access to the originator biologic drug because their insulin pump has not yet been approved for use with the biosimilar should have their physician submit an exception request. Patients enrolled in the Alberta Insulin Pump Therapy Program (IPTP) do not need to submit an exception request as an exemption will be in place until the biosimilar is approved for use.